# Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy

> **NCT00877500** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 116 (estimated)

## Conditions studied

- Bilateral Breast Carcinoma
- HER2/Neu Negative
- Invasive Breast Carcinoma

## Interventions

- **OTHER:** Best Practice
- **DRUG:** Ixabepilone

## Key facts

- **NCT ID:** NCT00877500
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2009-03-30
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 116 (ESTIMATED)
- **Last updated:** 2025-11-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00877500

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00877500, "Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy". Retrieved via AI Analytics 2026-09-08 from https://api.ai-analytics.org/clinical/NCT00877500. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*